@article{e217765f765f423eaf0c9be435b484d0,
title = "Cross disorder comparisons of brain structure in schizophrenia, bipolar disorder, major depressive disorder, and 22q11.2 deletion syndrome: A review of ENIGMA findings",
abstract = "This review compares the main brain abnormalities in schizophrenia (SZ), bipolar disorder (BD), major depressive disorder (MDD), and 22q11.2 Deletion Syndrome (22q11DS) determined by ENIGMA (Enhancing Neuro Imaging Genetics through Meta Analysis) consortium investigations. We obtained ranked effect sizes for subcortical volumes, regional cortical thickness, cortical surface area, and diffusion tensor imaging abnormalities, comparing each of these disorders relative to healthy controls. In addition, the studies report on significant associations between brain imaging metrics and disorder-related factors such as symptom severity and treatments. Visual comparison of effect size profiles shows that effect sizes are generally in the same direction and scale in severity with the disorders (in the order SZ > BD > MDD). The effect sizes for 22q11DS, a rare genetic syndrome that increases the risk for psychiatric disorders, appear to be much larger than for either of the complex psychiatric disorders. This is consistent with the idea of generally larger effects on the brain of rare compared to common genetic variants. Cortical thickness and surface area effect sizes for 22q11DS with psychosis compared to 22q11DS without psychosis are more similar to those of SZ and BD than those of MDD; a pattern not observed for subcortical brain structures and fractional anisotropy effect sizes. The observed similarities in effect size profiles for cortical measures across the psychiatric disorders mimic those observed for shared genetic variance between these disorders reported based on family and genetic studies and are consistent with shared genetic risk for SZ and BD and structural brain phenotypes.",
keywords = "ENIGMA, bipolar disorder, major depressive disorder, schizophrenia, velocardiofacial",
author = "Eun-Jin Cheon and Bearden, {Carrie E.} and Daqiang Sun and Ching, {Christopher R. K.} and Andreassen, {Ole A.} and Lianne Schmaal and Veltman, {Dick J.} and Thomopoulos, {Sophia I.} and Peter Kochunov and Neda Jahanshad and Thompson, {Paul M.} and Turner, {Jessica A.} and {van Erp}, {Theo G. M.}",
note = "Funding Information: The research studies produced by the ENIGMA Working Groups would not be possible without the contributions of many researchers across the globe and the authors of this review thank all scientists who contribute to making this work possible. A full list of ENIGMA Consortium current and past members can be found here http://enigma.ini.usc.edu/ongoing/members/ . The authors acknowledge the NIH Big Data to Knowledge (BD2K) award for foundational support and consortium development (U54 EB020403 to PMT) and support from NIMH R01MH116147 (PMT), NIMH R01MH121246 (JAT, TGMvE, VDC), NIMH R01MH117601 (NJ, LS), NIMH R01MH085953 (CEB), NIMH R21MH116473 (CEB), NIMH 1U01MH119736 (CEB). For a complete list of ENIGMA‐related grant support please see here: http://enigma.ini.usc.edu/about-2/funding . Funding Information: Authors CRKC, NJ, and PMT received partial research support from Biogen, Inc., for research unrelated to this manuscript. OAA is a consultant to HealthLytix, and has received speaker's honorarium from Lundbeck and Sunovion. None of the other authors have any conflicts or competing interests to report. Publisher Copyright: {\textcopyright} 2022 The Authors. Psychiatry and Clinical Neurosciences {\textcopyright} 2022 Japanese Society of Psychiatry and Neurology.",
year = "2022",
month = may,
doi = "10.1111/pcn.13337",
language = "English",
volume = "76",
pages = "140--161",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",
}